Renal Cell Carcinoma Clinical Trials

90 recruiting

Renal Cell Carcinoma Trials at a Glance

192 actively recruiting trials for renal cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 2 with 79 trials, with the heaviest enrollment activity in Houston, Dallas, and New York. Lead sponsors running renal cell carcinoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and National Cancer Institute (NCI).

Browse renal cell carcinoma trials by phase

Treatments under study

About Renal Cell Carcinoma Clinical Trials

Looking for clinical trials for Renal Cell Carcinoma? There are currently 90 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 192 trials

Recruiting
Phase 2

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Advanced Renal Cell Carcinoma (aRCC)
Brian Rini120 enrolled1 locationNCT07188896
Recruiting

DESTINY-PANTUMOUR04

Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled25 locationsNCT05536141
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled3 locationsNCT07419841
Recruiting
Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting
Not Applicable

Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT

Renal Cell Carcinoma
Sunnybrook Health Sciences Centre70 enrolled1 locationNCT05023265
Recruiting
Phase 3

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.720 enrolled44 locationsNCT07011719
Recruiting
Phase 2

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Clear Cell Renal Cell Carcinoma+2 more
City of Hope Medical Center62 enrolled2 locationsNCT07037004
Recruiting
Phase 3

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled103 locationsNCT07227402
Recruiting
Phase 1Phase 2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+2 more
AstraZeneca60 enrolled11 locationsNCT07115043
Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Melanoma (Skin Cancer)Renal Cell Carcinoma (Kidney Cancer)Breast Cancer (Triple Negative Breast Cancer (TNBC))
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting
Phase 2

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+1 more
Vanderbilt-Ingram Cancer Center54 enrolled6 locationsNCT05361720
Recruiting
Phase 2

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Renal Cell Carcinoma+3 more
National Cancer Institute (NCI)65 enrolled13 locationsNCT04981509
Recruiting
Phase 1Phase 2

Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma

Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Beijing Biotech36 enrolled1 locationNCT07551349
Recruiting
Phase 1Phase 2

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Metastatic Renal Cell CarcinomaCarcinoma, Renal CellAdvanced Renal Cell Carcinoma+8 more
Pfizer224 enrolled49 locationsNCT07227415
Recruiting
Phase 1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Urothelial CarcinomaRenal Cell CarcinomaCastration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC60 enrolled4 locationsNCT06966024
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Endometrial CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+10 more
Rahul Aggarwal89 enrolled3 locationsNCT03682289
Recruiting
Phase 2

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

Renal Cell Carcinoma
Diwakar Davar880 enrolled1 locationNCT07223424